Most stable structures of polyhydroxylated endohedral metallofullerene Gd@C82(OH)x (x=1–24) from density function theory

Zhang, Junfeng; Li, Fengyu; Miao, Xiang-Yang; Zhao, Jijun; Long, Jing; Yang, Guohui; Jia, Xiaofang

doi:10.1016/j.cplett.2010.04.007

Cited by 15 publications

(11 citation statements)

References 27 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the theoretically predicted most stable structure of Gd@C 82 (OH) 22 is that with hydroxyls around the C 82 cage in a more homogenous and scattered manner ( Fig. 1a-B,C) 21 . Such different geometries and the associated physical properties may serve as an origin of differential biological effects of Gd@C 82 (OH) 22 and C 60 (OH) 22 .…”

Section: Resultsmentioning

confidence: 64%

Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor

Liu

Chen

Qian

et al. 2016

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 64%

Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor

Liu

Chen

Qian

et al. 2016

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

“…In contrast, the theoretically predicted most stable structure of Gd@C 82 (OH) 22 is that with hydroxyls around the C 82 cage in a more homogenous and scattered manner ( Fig. 1a–B,C ) 21 . Such different geometries and the associated physical properties may serve as an origin of differential biological effects of Gd@C 82 (OH) 22 and C 60 (OH) 22 .…”

Section: Resultsmentioning

confidence: 83%

Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor

et al. 2015

View full text Add to dashboard Cite

The contemporary use of nanomedicines for cancer treatment has been largely limited to serving as carriers for existing therapeutic agents. Here, we provide definitive evidence that, the metallofullerenol nanomaterial Gd@C82(OH)22, while essentially not toxic to normal mammary epithelial cells, possesses intrinsic inhibitory activity against triple-negative breast cancer cells. Gd@C82(OH)22 blocks epithelial-to-mesenchymal transition with resultant efficient elimination of breast cancer stem cells (CSCs) resulting in abrogation of tumour initiation and metastasis. In normoxic conditions, Gd@C82(OH)22 mediates these effects by blocking TGF-β signalling. Moreover, under hypoxic conditions found in the tumour microenvironment, cellular uptake of Gd@C82(OH)22 is facilitated where it functions as a bi-potent inhibitor of HIF-1α and TGF-β activities, enhancing CSC elimination. These studies indicate that nanomaterials can be engineered to directly target CSCs. Thus, Gd-metallofullerenol is identified as a kind of non-toxic CSC specific inhibitors with significant therapeutic potential.

show abstract

“…[54, 55] The endohedral metallofullerenes Gd@C 20 ‐glycine was also considered and explored, due to the fact that the derivatives containing Gd atom produce some interesting physical properties. [56–59] The Gd@C 20 ‐glycine is also carried out as a hypothetical system, not available, but the study may stimulate further efforts for its isolation. Thus, it is very interesting for us to explore the structures, stabilities, and electronic properties of C 20 ‐glycine and Gd‐encapsulated derivative with the aid of quantum chemical calculations.…”

Section: Introductionmentioning

confidence: 99%

Understanding why rheumatoid arthritis patient treatment preferences differ by race

Constantinescu

Goucher

Weinstein

et al. 2009

Arthritis & Rheumatism

View full text Add to dashboard Cite

Background Rheumatoid arthritis (RA) patient preferences may account for some of the variability in treatment amongst different racial groups. How and why treatment preferences differ by race is not well understood. We sought to determine whether Black and White RA patients differ in how they evaluate the specific risks and benefits related to medications. Methods 136 RA patients completed a conjoint analysis interactive computer survey to determine how they valued the specific risks and benefits related to treatment characteristics. We calculated the importance that respondents assigned to each characteristic and the ratio of the importance that patients attached to overall benefit versus overall risk. Subjects having a risk ratio of less than one were classified as being risk averse. Results The mean age of the study sample was 55 years (range 22–84), 49% were Black and 51% were White. Black subjects assigned the greatest importance to the risk of cancer, whereas White subjects were most concerned with the likelihood of remission and halting radiographic progression. Fifty-two percent of Black subjects were found to be risk averse compared to 12% of the White subjects (p<0.0001). Race remained strongly associated with risk aversion [adjusted odds ratio (95% CI) = 8.4 (3.1 – 23.1)] after adjusting for relevant covariates. Conclusions Black patients attach greater importance to the risks of toxicity and less importance to the likelihood of benefit than their White counterparts. Effective risk communication and improved understanding of expected benefits may help decrease unwanted variability in healthcare.

show abstract

Most stable structures of polyhydroxylated endohedral metallofullerene Gd@C82(OH)x (x=1–24) from density function theory

Cited by 15 publications

References 27 publications

Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor

Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor

Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor

Understanding why rheumatoid arthritis patient treatment preferences differ by race

Contact Info

Product

Resources

About